

Hugh S Griffith
Chief Executive Officer
T: +44 (0) 131 248 3660
E: info@nucanabiomed.com
W: www.nucanabiomed.com

## NuCana Invited to Present at BioEquity Europe on Wednesday 22nd May 2013

Hugh Griffith, CEO of NuCana BioMed, will present at the 14th BioEquity Europe conference on 22nd May, in Stockholm, Sweden.

BioEquity Europe is the premier industry event for leading emerging companies in the life sciences to access top financial dealmakers, showcasing over 80 prominent European companies to selected investment and senior life sciences professionals.

Hugh Griffith stated: "I am delighted to present our ProTide technology which has been designed to overcome key cancer resistance mechanisms and is already showing impressive results in the clinic."

## About NuCana BioMed

Headquartered in Edinburgh, UK, NuCana BioMed is a clinical stage biopharmaceutical company developing and commercialising a range of exciting, new anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.